L & S Advisors Inc Allakos Inc. Transaction History

L & S Advisors Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$85.37 - $114.1 $256,110 - $342,300	-3,000 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$109.73 - $153.66 $109,730 - $153,660	1,000 Added 50.0%	3,000 $344,000
Q4 2020 Feb 16, 2021	BUY	$79.58 - $152.45 $159,160 - $304,900	2,000 New	2,000 $280,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $79.6M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of L & S Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on L & S Advisors Inc with notifications on news.